博济医药(300404) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥138,861,747.84, a decrease of 17.06% compared to ¥167,424,382.67 in the same period last year[5] - The net profit attributable to shareholders was ¥3,900,579.72, down 76.38% from ¥16,513,092.18 year-on-year[5] - The basic earnings per share decreased to ¥0.0102, down 76.39% from ¥0.0432 in the same period last year[5] - The total comprehensive income for the period was ¥4,597,792.32, a decrease of 74.20% compared to ¥17,821,249.12 in the previous year[12] - Operating profit for the current period is CNY 3,903,457.70, a decline of 76.5% from CNY 16,614,526.52 in the previous period[26] - Net profit for the current period is CNY 3,843,087.85, down 77.0% from CNY 16,631,692.07 in the previous period[26] - The net profit attributable to the parent company was 3,900,579.72 yuan, a decrease from 16,513,092.18 yuan in the previous period, representing a decline of approximately 76.4%[27] - The total comprehensive income attributable to the parent company was 3,818,213.24 yuan, down from 17,076,703.66 yuan, indicating a decrease of about 77.7%[27] Cash Flow - The net cash flow from operating activities improved significantly to ¥8,828,695.62, compared to a negative cash flow of ¥15,764,811.36 in the previous year, representing a 156.00% increase[5] - Cash inflows from operating activities totaled 189,364,292.08 yuan, compared to 142,260,961.86 yuan in the prior period, reflecting an increase of approximately 33.2%[29] - Cash outflows from operating activities were 180,535,596.46 yuan, up from 158,025,773.22 yuan, marking an increase of about 14.3%[30] - The net cash flow from investing activities was -130,073,402.19 yuan, slightly improved from -153,727,515.94 yuan in the previous period[30] - The net cash flow from financing activities was 4,518,319.16 yuan, compared to a net outflow of 8,523,943.30 yuan in the prior period, indicating a turnaround[30] - The ending cash and cash equivalents balance was 151,790,383.34 yuan, down from 217,196,523.19 yuan, a decrease of approximately 30.1%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,491,435,459.66, reflecting a 2.82% increase from ¥1,450,592,225.50 at the end of the previous year[5] - Total current assets increased to CNY 823,520,451.16 from CNY 780,278,696.05, representing a growth of 5.0%[24] - Total non-current assets decreased slightly to CNY 667,915,008.50 from CNY 670,313,529.45, a decline of 0.4%[25] - Total liabilities increased to CNY 477,087,563.67 from CNY 448,838,881.46, an increase of 6.3%[25] - Total equity attributable to shareholders increased to CNY 985,275,784.42 from CNY 973,381,474.22, a growth of 1.0%[26] - Cash and cash equivalents decreased to CNY 153,365,620.33 from CNY 270,133,867.18, a decline of 43.2%[24] - Inventory increased to CNY 220,311,229.03 from CNY 189,485,440.64, an increase of 16.3%[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 26,693[15] - The largest shareholder, Wang Tingchun, holds 30.97% of the shares, amounting to 118,674,370 shares, with 89,005,777 shares pledged[16] - The top 10 shareholders hold a total of 89,005,777 shares, with no changes in the number of restricted shares during the period[19] - The total number of restricted shares at the end of the period was 105,113,676 shares, with 1,422,750 shares released during the period[19] - The company has a repurchase special account holding 2,667,000 shares, accounting for 0.70% of the total share capital[19] - The company’s major shareholder, Wang Tingchun, holds 29,668,593 shares, representing a significant portion of the total shares[18] - The company’s major shareholder, Zhao Lingli, holds 4,804,905 shares, indicating strong insider ownership[18] - The company has established a unified action relationship among certain shareholders, enhancing governance and decision-making[18] Research and Development - The company successfully passed the GLP certification review and received the new "Drug GLP Certification" with a total of 8 certification qualifications[20] - The company signed a technology transfer contract with Shaanxi Panlong Pharmaceutical Group, transferring the technology for "Glucosamine Sulfate Capsules" for a total fee of RMB 4.5 million[20] - The company's subsidiary, Huasheng Pharmaceutical, received approval for the listing application of "Sodium Sulfate" from the National Medical Products Administration[21] - In the first quarter of 2025, the company and its subsidiaries obtained seven invention patents from the National Intellectual Property Administration[21] Return on Equity - The weighted average return on equity was 0.40%, a decline of 1.32% from 1.72% in the previous year[5]